CDNA (US)

CMS’s preliminary CY27 rates for lab codes targeted through the next phase of adjustments under the Protecting Access to Medicare Act (PAMA), released last night, appear largely consistent with the ~$100 M risk projections previously…

Today’s final coverage decision on organ allograft rejection testing represents a clear positive for CareDx (CDNA), with meaningful improvements over both last year’s initial proposal and even our own expectations, likely neutralizing what had been…

We view CareDx (CDNA) as having potentially asymmetric downside risk going into the final MolDx local coverage determination (LCD) on organ transplant rejection, which we would expect to be released in the next 1-2 months…